---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-22-007530"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T22:54:57.441883+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Phio Q3 net loss $3.6M, cash $14.5M; appoints Bitterman, Mahoney, Spellman

## Summary
- New appointments: Robert Bitterman as Interim Executive Chairman, Linda Mahoney as VP of Project Development, Dr. Mary Spellman as medical advisor.
- Cash at Sept 30, 2022: $14.5M, down from $24.1M at Dec 31, 2021; expects to fund operations for at least 12 months.
- Net loss $3.6M ($0.26/share) vs $3.7M ($0.28) in Q3 2021; R&D expenses down 6% to $2.5M.
- Phase 1b study of PH-762 for advanced melanoma continues enrollment; top-line data expected Q1 2023.
- Plans to initiate trial with AgonOx in Q4 2022; IND-enabling studies for PH-894 by year end.

## SEC filing metadata
- accession: 0001683168-22-007530
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000168316822007530/0001683168-22-007530-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000168316822007530/phio_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-22-007530
- JSON: https://secwatch.observer/filing/0001683168-22-007530.json
- Plain text: https://secwatch.observer/filing/0001683168-22-007530.txt

## Key facts
- Earnings Releases
  Phio Pharmaceuticals Corp. reported the quarter ended September 30, 2022 results: net income approximately $3.6 million, or $0.26 per share, EPS $0.26 per share.
  - Period: the quarter ended September 30, 2022
  - Net income: approximately $3.6 million, or $0.26 per share
  - EPS: $0.26 per share
  - Result: reported results
  source text: Net loss decreased 4% to approximately $3.6 million, or $0.26 per share, for the quarter ended September 30, 2022, compared with $3.7 million, or $0.28 per share, for the quarter ended September 30, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1533040/000168316822007530/0001683168-22-007530-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.